Business Context and Reporting Period
This Form 8-K reports on the results of the 2022 Annual Meeting of Stockholders for Madrigal Pharmaceuticals, Inc., held virtually on June 15, 2022. The report was filed on June 17, 2022.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
As of the record date (April 27, 2022), the company had 17,103,395 shares of common stock outstanding. A quorum was established with 14,783,850 shares present or represented by proxy. The following proposals were submitted to a vote:
- Proposal 1 (Election of Directors): Stockholders elected three Class III nominees to the Board of Directors for a three-year term expiring in 2025.
- Keith Gollust: 9,614,291 votes For; 2,151,943 votes Withheld.
- Richard Levy, M.D.: 10,485,539 votes For; 1,280,695 votes Withheld.
- David Milligan, Ph.D.: 11,649,813 votes For; 116,421 votes Withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Votes For: 14,712,949
- Votes Against: 19,842
- Votes Abstaining: 51,058
- Proposal 3 (Say-on-Pay): Stockholders approved, on an advisory basis, the compensation of named executive officers with 99.0% of votes cast in favor.
- Votes For: 11,637,547
- Votes Against: 111,932
- Votes Abstaining: 16,755
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a procedural report regarding the Annual Meeting.
Important Facts for Investors to Verify
- Confirmation that the three Class III director nominees (Gollust, Levy, Milligan) have officially assumed their roles on the Board.
- Verification of the engagement of PricewaterhouseCoopers LLP for the 2022 fiscal year audit.
- Review of the Proxy Statement filed on May 2, 2022, for detailed descriptions of the proposals and executive compensation details.